
    
      Eligible participants will complete a 6-month Observation Phase, followed by a 24-month
      Treatment Phase, followed by an End of Study Visit. Eligible participants will be randomized
      at Month 6 in a 1:1 ratio to either ORACEA (40 mg doxycycline) or placebo capsule to be taken
      once-daily for 24 months. Over the course of the 31-month study, a total of 9 clinic visits
      and 3 telephone calls are required.
    
  